FDA Approved: NETSPOT — Supplemental Application (Advanced Accelerator Applications USA, Inc)

View source ↗

Summary

FDA approved a supplemental application for NETSPOT (68Ga-DOTATATE), a radiopharmaceutical imaging agent for somatostatin receptor–positive neuroendocrine tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• NETSPOT (gallium-68 DOTATATE)

Snippet

SUPPL AP for NETSPOT (68GA-DOTATATE)